-
Mashup Score: 1Safety Signal in Phase 2 Deals a Setback to BioAge Labs’ Muscle-Preserving Obesity Drug - MedCity News - 2 day(s) ago
BioAge Labs said the potential safety problem was observed in some who received experimental drug azelaprag, which is being tested as a monotherapy and in combination with Eli Lilly obesity medication Zepbound. No safety signals were observed in those who received Zepbound alone.
Source: medcitynews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2Coverage for these drugs is being dropped for thousands in Michigan. Patients are angry - 4 month(s) ago
Some patients who’ve found success with the medications are angry that insurance issues could derail access to them.
Source: www.detroitnews.comCategories: General Medicine News, General HCPsTweet-
Our medical director of weight management and #obesity medicine Dr. Suki Singh sat down with @detroitnews to explain how #weightloss medications work and what may happen if you stop taking them. Learn more: https://t.co/1Vr7ITYLG9 https://t.co/DtmTxs9Ga2
-
-
Mashup Score: 0‘The Time Is Now’: How Employers Can Offer Comprehensive Obesity Care - MedCity News - 7 month(s) ago
Employers are in a unique position to drive change in obesity care, but face several challenges. Experts shared numerous strategies employers can implement.
Source: medcitynews.comCategories: General Medicine News, General HCPsTweet-
‘The Time Is Now’: How Employers Can Offer Comprehensive #Obesity Care - Employers are in a unique position to drive change in obesity care, but face several challenges. Experts shared numerous strategies employers can implement | #weightloss https://t.co/MC0knjLM1h
-
BioAge Labs' drug Azelaprag aimed to preserve muscle during weight loss but a safety signal halted its Phase 2 test, months after a $200M IPO driven by high hopes. https://t.co/onoqUeexAv #obesity #weightloss $BIOA